Page 28 - 《中国药房》2024年23期
P. 28

《湖北省三级妇幼保健院评审标准(2024 年版)》药事管理条款

          研究     Δ



                                                           5 #
                                                   2
                           2
                                           4
                 1*
          赵琳琳 ,卢圆圆 ,刘茂昌 ,金 帆 ,庞良芳 ,付 伟 (1.中部战区总医院临床药学科,武汉 430070;2.湖北
                                   3
          省妇幼保健院药学部,武汉 430064;3.武汉儿童医院药学部,武汉 430019;4.宜昌妇幼保健院药学部,湖北
          宜昌 443000;5.华中科技大学同济医学院附属同济医院药学部,武汉 430030)
          中图分类号  R951      文献标志码  A      文章编号  1001-0408(2024)23-2858-05
          DOI  10.6039/j.issn.1001-0408.2024.23.04


          摘   要  目的  对《湖北省三级妇幼保健院评审标准(2024 年版)》(简称《2024 版湖北妇幼标准》)中的药事管理条款进行研究。
          方法  阐述《2024版湖北妇幼标准》中药事管理条款和管理细则的制定过程,同时比较其药事管理条款与《三级妇幼保健院评审标
          准(2016年版)》中药事管理条款的异同,分析其药事管理特有条款的制定依据,并在此基础上提出进一步改进的建议。结果与结论
          与《三级妇幼保健院评审标准(2016年版)》比较,《2024版湖北妇幼标准》中涉及药事管理的相同点主要体现在:应遵守的相关法
          律、法规、规章制度及人员要求,药品采购、储备、贮存及召回全流程管理,药品调剂与制剂管理等方面;《2024版湖北妇幼标准》特
          有条款主要体现在:成立儿童用药工作组,建立儿童专用药品目录,制定结余药品管理制度和超说明书用药管理等方面。药事管
          理特有条款的制定既符合近年来国家新发布的政策要求,又结合了妇幼保健院的特点和实际情况。但《2024版湖北妇幼标准》应
          在加强细节管理、强化中药合理应用管理方面进一步完善。
          关键词  妇幼保健院;医院评审标准;药事管理;特殊人群

          Research  on  pharmaceutical  management  provisions  in  the  Evaluation  Standards  for  Third-level  Maternal

          and Child Health Care Hospitals in Hubei Province (2024 Edition)
                                                              4
                                                     3
                      1
                                     2
                                                                                2
          ZHAO Linlin ,LU Yuanyuan ,LIU Maochang ,JIN Fan ,PANG Liangfang ,FU Wei (1.  Dept.  of  Clinical
                                                                                         5
          Pharmacy,  General  Hospital  of  Central  Theater  Command,  Wuhan  430070,  China;2.  Dept.  of  Pharmacy,
          Women  and  Children’s  Hospital  of  Hubei  Province,  Wuhan  430064,  China;3.  Dept.  of  Pharmacy,  Wuhan
          Children’s  Hospital,  Wuhan  430019,  China;4.  Dept.  of  Pharmacy, Yichang  Women  and  Children’s  Hospital,
          Hubei  Yichang  443000,  China;5.  Dept.  of  Pharmacy,  Tongji  Hospital,  Tongji  Medical  College  of  Huazhong
          University of Science and Technology, Wuhan 430030, China)
          ABSTRACT    OBJECTIVE To study pharmaceutical management provisions in the Evaluation Standards for Third-level Maternal
          and Child Health Care Hospitals in Hubei Province (2024 Edition) (hereinafter referred to as 2024 Edition of Hubei Maternal and
          Child  Health  Care  Standards).  METHODS  The  formulation  of  pharmaceutical  management  clauses  and  management  rules  in  the
          2024  Edition  of  Hubei  Maternal  and  Child  Health  Care  Standards  was  elaborated  and  compared  with  the  pharmaceutical
          management  clauses  in  the  Evaluation  Standards  for  Third-level  Maternal  and  Child  Health  Care  Hospitals (2016  Edition)  to  find
          out their similarities and differences; the basis for the formulation of unique pharmaceutical management clauses was analyzed, so
          as to propose further improvement suggestions. RESULTS & CONCLUSIONS Compared with the Evaluation Standards for Third-
          level Maternal and Child Health Care Hospitals (2016 Edition), the similarities in pharmaceutical management in the 2024 Edition
          of  Hubei  Maternal  and  Child  Health  Care  Standards  were  mainly  reflected  in  the  relevant  laws,  regulations,  rules  and  personnel
          requirements  that  should  be  followed,  the  full  process  management  of  drug  procurement,  reserve,  storage  and  recall,  drug
          dispensing  and  formulation  management,  etc.  The  unique  provisions  of  the  2024  Edition  of  Hubei  Maternal  and  Child  Care
                                                              Standards  were  mainly  reflected  in  the  establishment  of
              Δ 基金项目 湖北省科技计划一般面上项目(No.2021CFB348);武           children’s  medication  working  group,  the  establishment  of  a
          汉药学会孵化营项目(No.WHPA202301051)                         list  of  children’s  specific  drugs,  the  development  of  surplus
             * 第一作者 主 管 药 师 。 研 究 方 向 :医 院 药 学 。 电 话 :027-
                                                              drug  management  system,  and  the  management  of  off-label
          50772992。E-mail:zhaolinlin0719@qq.com
                                                              drug  use,  etc.  The  formulation  of  unique  provisions  for
              #  通信作者 副主任药师。研究方向:医院药学。电话:027-
          83663084。E-mail:luis9@126.com                       pharmaceutical  management  not  only  conformed  to  the  newly


          · 2858 ·    China Pharmacy  2024 Vol. 35  No. 23                            中国药房  2024年第35卷第23期
   23   24   25   26   27   28   29   30   31   32   33